The term “non-alcoholic steatohepatitis” (NASH) was originally used to describe liver damage characterized by lobular inflammation, steatosis and ballooning of hepatocytes. In addition, a large proportion of patients were described as having “cryptogenic cirrhosis” at the time: The term “non-alcoholic fatty liver disease” (NAFLD) was established as the diagnosis for these patients.
Autoren
- PD Dr. med. Sena Blümel
- Prof. Dr. med. Christoph Jüngst
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- AI in neurology
Control instead of a flood of data: AI makes big data and wearables usable
- Participation of the patient
Adherence in psychiatry
- Eosinophilic esophagitis
EoE rarely occurs in isolation
- Lung cancer with EGFR mutation
New perspectives in first-line therapy
- Sleep disorder
Sleep medicine in transition: new goals and a reassessment of old hypnotics
- Ginkgo biloba extract in the Alzheimer's mouse model
Effects on disease-associated microglia subpopulations
- "Patients W.A.I.T Indicator"
Access to medicines – how does Switzerland compare across Europe?
- Osteoporosis